Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
32.28
-1.49 (-4.41%)
At close: Mar 3, 2026, 4:00 PM EST
33.15
+0.87 (2.70%)
Pre-market: Mar 4, 2026, 7:10 AM EST
Teva Pharmaceutical Stock Forecast
Stock Price Forecast
The 8 analysts that cover Teva Pharmaceutical stock have a consensus rating of "Strong Buy" and an average price target of $37.25, which forecasts a 15.40% increase in the stock price over the next year. The lowest target is $26 and the highest is $45.
Price Target: $37.25 (+15.40%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Teva Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 5 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 9 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $38 → $42 | Strong Buy | Maintains | $38 → $42 | +30.11% | Feb 18, 2026 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $36 → $45 | Strong Buy | Maintains | $36 → $45 | +39.41% | Feb 9, 2026 |
| Barclays | Barclays | Buy Maintains $35 → $38 | Buy | Maintains | $35 → $38 | +17.72% | Jan 30, 2026 |
| Scotiabank | Scotiabank | Buy Maintains $35 → $40 | Buy | Maintains | $35 → $40 | +23.92% | Jan 29, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $36 → $38 | Strong Buy | Maintains | $36 → $38 | +17.72% | Jan 29, 2026 |
Financial Forecast
Revenue This Year
17.05B
from 17.26B
Decreased by -1.23%
Revenue Next Year
17.55B
from 17.05B
Increased by 2.97%
EPS This Year
2.79
from 1.21
Increased by 130.28%
EPS Next Year
3.14
from 2.79
Increased by 12.64%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 17.9B | 18.5B | |
| Avg | 17.0B | 17.6B | |
| Low | 16.2B | 16.5B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 3.9% | 8.3% | |
| Avg | -1.2% | 3.0% | |
| Low | -6.3% | -3.2% |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | 2.97 | 3.32 |
| Avg | 2.79 | 3.14 |
| Low | 2.60 | 2.92 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | 145.6% | 19.1% |
| Avg | 130.3% | 12.6% |
| Low | 114.6% | 4.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.